# KORU Medical Systems, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/KORU Medical Systems, Inc.). ## Overview KORU Medical Systems develops, manufactures, and commercializes portable large-volume subcutaneous infusion solutions used to deliver drugs under the FREEDOM Infusion System brand. Its products are designed for home and specialty-care administration of therapies such as immunoglobulin for PIDD and CIDP, and the company also supports pharma clinical trials and customization work for biopharmaceutical customers. ## Products & services • FREEDOM60® Syringe Driver • FreedomEdge® Syringe Driver • HIgH-Flo Subcutaneous Safety Needle Sets™ • Precision Flow Rate Tubing™ • Pharma services and clinical trials support • Non-recurring engineering, testing, and registration services - **Mechanical infusion systems** (55%) — Portable syringe drivers and related devices used to infuse subcutaneous therapies. - **Consumables** (35%) — Needle sets and tubing used with the FREEDOM System for recurring patient use. - **Pharma services and clinical trials** (10%) — Product supply and support for feasibility studies and clinical trial programs. - FREEDOM60® Syringe Driver - FreedomEdge® Syringe Driver - HIgH-Flo Subcutaneous Safety Needle Sets™ - Precision Flow Rate Tubing™ - Pharma services and clinical trials support - Non-recurring engineering, testing, and registration services ## Customers KORU sells mainly to specialty pharmacies, home infusion providers, pharmaceutical companies, and medical device distributors. These customers buy the FREEDOM System because it supports subcutaneous delivery of immunoglobulin and other therapies, often in home or ambulatory settings where portability and ease of use matter. The company also serves biopharma customers that need clinical-trial supply, testing, and customization support before broader commercialization. - **Specialty pharmacies** (primary) — Buy drivers, tubing, and needle sets for patients receiving immunoglobulin at home; they value one-stop purchasing and inventory management. - **Home infusion providers** (primary) — Purchase the FREEDOM System for subcutaneous drug administration in home-care settings where portability and patient convenience matter. - **Medical device distributors** (primary) — Resell KORU products and account for a large share of revenue; they matter because purchasing patterns can swing quarterly results. - **Pharmaceutical and biopharma companies** (secondary) — Buy product supply and engineering support for feasibility studies, clinical trials, and commercialization readiness. - **Hospitals and ambulatory service providers** (secondary) — Use the system for subcutaneous drug delivery in clinical settings and outpatient care. - Specialty pharmacies buying for patient home-use therapy fulfillment - Home infusion providers needing portable subcutaneous delivery systems - Pharmaceutical companies using the system in clinical trials - Medical device distributors that aggregate and resell to end customers - Hospitals and ambulatory providers serving immunoglobulin patients ## Geography KORU’s core business is split between domestic core revenue, which includes the U.S. and Canada, and international core revenue from markets outside North America. Manufacturing is concentrated in Mahwah, New Jersey, with additional contract manufacturing in Nicaragua for needle sets and tubing, making supply continuity and cross-border logistics important to execution. - **Domestic core** (71.9%) — Management disclosure groups U.S. and Canada together. - **International core** (25.2%) — Disclosed as international core without country detail. - **Pharma services and clinical trials** (2.9%) — Residual revenue category from segment disclosure. - Domestic core covers the U.S. and Canada - International core provides meaningful non-U.S. growth - Mahwah, New Jersey is the main manufacturing site - Nicaragua contract manufacturing supplies consumables - Distributor concentration makes regional execution important ## Strategy KORU’s strategy centers on expanding adoption of the FREEDOM System in subcutaneous drug delivery while broadening its customer base beyond a small set of distributors. It is also investing in international expansion, new product introductions, and pharma-services relationships to diversify revenue and support longer-term growth. - **Broaden distribution and reduce concentration** (short-term) — A few distributors drive most revenue, so expanding channels lowers dependency and improves resilience. - **International expansion** (medium-term) — Non-U.S. growth can diversify the business and increase the installed base of the FREEDOM System. - **Product innovation and clinical customization** (medium-term) — New devices and services help defend against competition and support biopharma commercialization. - Expand FREEDOM System adoption in subcutaneous drug delivery - Grow international core revenue beyond the U.S. and Canada - Develop new products and accessories to stay competitive - Deepen pharma services and clinical trial relationships - Manage supply chain and manufacturing resilience across sites ## Risks KORU is exposed to customer concentration, distributor dependence, and competitive pressure in a medical-device market where larger peers and consolidating buyers can push pricing lower. Its business also depends on regulatory compliance, reimbursement dynamics, and uninterrupted manufacturing across its U.S. and Nicaragua supply chain. - **Distributor concentration** [high] — A small number of distributors account for most net revenue, so order timing and purchasing patterns can swing results. - **Manufacturing and supply chain disruption** [high] — Production is split between Mahwah and Nicaragua, and any site outage or border/logistics issue could delay shipments. - **Competitive and pricing pressure** [medium] — Consolidation among medical device buyers and suppliers can increase bargaining power and force price reductions. - **Regulatory and reimbursement changes** [high] — Demand depends on FDA clearance, payer coverage, and reimbursement for the therapies delivered with the system. - **Technology obsolescence** [medium] — If KORU fails to introduce new products or keep pace with infusion technology, customers may switch to alternatives. - Heavy reliance on a small number of distributors - Pricing pressure from consolidation among buyers and competitors - Regulatory and reimbursement changes can reduce demand - Manufacturing or logistics disruption could halt supply - New technologies may displace current infusion solutions ## Accounting Revenue is recognized at shipment for product sales, so quarterly results can be affected by distributor ordering patterns and shipment timing. Investors should also watch estimates tied to warranties, inventory, and any financing or capital-raising needs, since the company has discussed ongoing cash usage and potential future funding requirements. - **Revenue recognition at shipment** — Quarterly comparability - **Warranty accruals** — Gross margin and operating expense - **Inventory valuation** — Working capital and cost of sales - **Liquidity and financing assumptions** — Capital structure and dilution risk - Product revenue is recognized when shipment occurs - Distributor ordering patterns can shift quarterly revenue timing - Warranty costs are expensed as incurred - Inventory levels and obsolescence risk affect working capital - Insurance premium financing and stock option exercises affect cash flows --- *Last updated: 2026-04-28T20:19:45.758031+00:00*